How to Turn a Trillion-Dollar Trend Into a Windfall Opportunity of Your Own
You’re cordially invited to attend a special online event to introduce my new trading service, FirstLine Investor Alert.
On this webinar, I’ll give you the specific names and ticker symbols of the companies behind the three opportunities I’ve just discussed.
I’ll go over everything I’ve uncovered about these situations…
The timeline, the technology… the potential risks, rewards, and, of course, the identity of these companies, which I believe could make early shareholders an absolute fortune.
I’ll also tell you all about one additional innovative company… that I believe may be the best healthcare company you can own right now.
I’ll give you all the details on this event in a moment. But first let me explain why it’s critical that you RSVP as soon as possible.
Trillions of Dollars Changing Hands
My primary objective with FirstLine Investor Alert is to uncover the biggest profit opportunities coming from the explosion of healthcare spending in America.
As Oxford Club Investment Director Alexander Green says, “The planets are perfectly aligned for healthcare right now.”
In completing our extensive research into the markets at the beginning of the year, Alex and I both quickly pinpointed healthcare and medical technology as the number one sector to invest in for 2012…
And it became obvious this opportunity called for a forum of its own…
A way for our members to take advantage of the urgent, aggressive opportunities in this sector, and a way to capture the greatest potential profits.
And with my 15 years of experience in the field, Alex and my publishers agreed I’d be the ideal leader for our new FirstLine Investor Alert service.
Alex also understands that in recent years, I’ve led subscribers to impressive returns with investments in my other portfolios, including…
- 103% gains in just over 7 months, on a $400 million company whose lead product can increase the effectiveness of dozens of other company’s drugs…
- 128% gains in just over a year, on a company that develops treatments for potential bio-terror attacks…
- Even 211% returns in less than 5 months, on another “bio-defense” firm that battles biological and chemical weapons.
And these gains are from stocks, not options!
Now, you’re invited to get the same level of information to capitalize on the coming healthcare money slam.
I hope you’ll join me, and take a trial subscription for my new service, FirstLine Investor Alert.
You’ll Get Details of Meetings With CEOs and Hedge Fund Managers
With FirstLine Investor Alert, you’ll get research, insight and recommendations on up-and-coming companies…
Intelligence you can’t possibly get from any other investment service or broad-market “guru.”
We call this service FirstLine Investor Alert because in the medical field, “first line” drugs refer to those most successful, powerful drugs doctors are likely to choose to improve a patient’s health.
With this new service, I’ll aim to improve the “health” of your portfolio… by uncovering the most powerful and successful investment opportunities in the healthcare industry.
Remember, when small healthcare companies develop innovative products… the returns for early shareholders can be mind-boggling:
- For example, Amgen developed a breakthrough drug in the late 1980s called Epogen to treat kidney problems. To date, Amgen has soared an astronomical 17,677%.
- In July of 1998, Celgene released Thalomid, a leprosy treatment, and in March of 2006, the drug was rereleased as a blood cancer treatment. Since its initial release, shares have risen as much as 2,299%.
- And in the early 1990s, Medtronic was trading for an adjusted price of less than $2.00 per share. But thanks to their innovative development of the PCD heart defibrillator in 1993, shares have climbed as much as 1,795%.
These were all remarkable advances, no doubt.
But what I foresee in the months ahead stands to blow everything else out of the water…
Page 7
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9
[cfsp name="joinnow"]